Neurocrine (NBIX) Biosciences announced the presentation of new data from the Phase 2 SAVITRI study, which showed statistically significant and clinically meaningful improvement in depression severity at Day 28 and Day 56 with once-daily oral administration of 1 mg osavampator. In recognition of the data presentation, Neurocrine was honored with the 2025 Poster Award at the 38th annual Psych Congress in San Diego. The study met its primary efficacy endpoint, showing a significant reduction in depression severity from baseline to Day 28 compared to placebo, as measured by the Montgomery-Asberg Depression Rating Scale total score. Secondary efficacy endpoints included the change in MADRS total score from baseline to Day 56.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine’s Osavampator Shows Promising Phase 2 Results, Boosting Buy Rating and Stock Price Target
- Promising Potential of Neurocrine’s Osavampator in Treating Major Depressive Disorder: A Buy Recommendation by Sean Laaman
- Neurocrine price target raised to $149 from $144 at RBC Capital
- Neurocrine’s Strong Market Performance and Promising Pipeline Justify Buy Rating
- Promising Growth and Strategic Positioning Drive Buy Rating for Neurocrine